The renin angiotensin system in the regulation of angiogenesis

Current Pharmaceutical Design

Volumn 13, Issue 12, 2007, Pages 1215-1229

  Heffelfinger, Sue C ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiotensin; Angiotensin converting enzyme; Bradykinin; Cancer; Ischemia; Kininogen; Stroke

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 [3 (ACETYLTHIO) 3 BENZOYL 2 METHYLPROPIONYL]PROLINE; ATENOLOL; BATIMASTAT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; INDAPAMIDE; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; OLMESARTAN; PENICILLAMINE; PENTOPRIL; PERINDOPRIL; QUINAPRILAT; RAMIPRIL; RECOMBINANT VASCULOTROPIN; SARALASIN; SPIRAPRIL; TELMISARTAN; TEMOCAPRIL; UNINDEXED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUNG CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 34248345563     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780618858     Document Type: Review

References (216)

1. Oliverio M, Kim H-S, Ito M, Le T, Audoly L, Best C, et al. Reduced growth, abnormal kidney structure, and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci USA 1998; 95: 15496-501.
2. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998; 101: 755-60.
3. Bhoola K, Figueroa C, Worthy K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
4. Wu Z, Zheng W, Sandberg K. Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. Endocrinology 2003; 144: 1350-6.
5. Schmitz U, Berk B. Angiotensin II signal transduction: Stimulation of multiple mitogen-activated protein kinase pathways. Trends Endocrinol Metab 1997; 8: 261-6.
6. De Gasparo M, Catt K, Inagami T, Wright J, Unger T. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
7. Marrero M, Schieffer B, Paxton W, Heerdt L, Berk B, Delafontaine P, et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375: 247-50.
8. Seshiah P, Weber D, Rocic P, Valppu L, Taniyama Y, Griendler K. Angiotensin II stimulation of NAD(P)H oxidase activity upstream mediators. Circ Res 2002; 91: 406-13.
9. Voisin L, Foisy S, Giasson E, Lambert C, Moreau P, Meloche S. EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 2001; 283: C446-55.
10. Hansen J, Theilade J, Saunso s, Sheikh S. Oligomerization of wild type and nonfunctional mutant angiotensin II type 1 receptors inhibits Galphaq protein signaling but not ERK activation. J Biol Chem 2004; 279: 24108-15.
11. Wolf G, Wenzel U, Burns K, Harris R, Stahl R, Thaiss F. Angiotensin II activates nuclear transcription factor-kB through AT1 and AT2 receptors. Kid Int 2002; 61: 1986-95.
12. Brasier A, Jamaluddin M, Han Y, Patterson C, Runge M. Angiotensin II induces gene transcription through cell-type dependent effects on the nuclear factor-KB (NF-kB) transcription factor. Mol Cell Biol 2000; 212: 155-69.
13. Sandmann S, Yu M, Kaschina E, Unger T. Differential roles of AT1 and AT2 receptor subtypes in the expression of Na+-HCO3-symporter and Na+H+ exchanger in the rat heart after myocardial infarction. Dtsch Med Wochschr 1999; 124: S97 (P71).
14. Ohashi H, Takagi H, Oh H, Suzuma K, Suzuma I, Miyamoto N, et al. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. Circ Res 2004; 94: 785-93.
15. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau V. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activating protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022-6.
16. Yamada T, Horiuchi M, Dzau V. Angiotenisn II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93: 156-60.
17. Bottari S, King I, Reichlin S, Dahlstroem L, Lydon N, de Gasparo M. The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity ann mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun 1992; 183: 206-11.
18. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, et al. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268: 543-6.
19. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, S, Takai S, Miyazaki M, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-35.
20. Lokuta A, Cooper C, Gaa S, Wang H, Rogers T. Angiotensin II stimulates the release of phospholipid derived second messengers through multiple subtypes in heart cells. J Biol Chem 1994; 269: 4832-8.
21. Feng Y-H, Sun Y, Douglas J. Gbetagamma-independent constitutive association of Galphas with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1. Proc Natl Acad Sci USA 2002; 99: 12049-54.
22. Nakajima M, Hutchinson H, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effect of the AT1 receptor: Gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663-7.
23. Marin-Castano M, Schanstra J, Hirtz C, Pesquero J, Pecher C, Girolami J-P, et al. B2 kinin receptor upregulation by cAMP is associated with BK-induced PGE2 production in rat mesangial cells. Am J Physiol 1998; 274: F532-40.
24. Igarashi J, Bernier S, Michel T. Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 12420-6.
25. Scholze T, Moskvina E, Mayer M, Just H, Kubista H, Boehm S. Sympathoexcitation by bradykinin involves Ca++-independent protein kinase C. J Neurosci 2002; 22: 5823-32.
26. Thuringer D, Maulon L, Frelin C. Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 2002; 277: 2028-32.
27. Miura S-I, Matsuo Y, Saku K. Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003; 41: 1118-23.
28. Chou M, Wang J, Fujita D. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells. BMC Biochem 2002; 3: 32.
29. Shibuya M, Vascular endothelial growth factor receptor-2: Its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003; 94: 751-6.
30. Kroll J,Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 252: 743-6.
31. Parenti A, Morbidelli L, Ledda F, Granger H, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001; 15: 1487-9.
32. Schanstra J, Bataille E, Marin-Castano M, Barascud Y, Hirtz C, Pesquero J, et al. The B1-agonist [des-Arg10]-kallidin activates transcription factor NF-kB and induces homologous upregulation of the bradykinin B1-receptor in cultured human lung fibroblasts. J Clin Invest 1998; 101: 2080-91.
33. Dixon B, Evanoff D, Fang W, Dennis M. Bradykinin B1 receptor blocks PDGF-induced mitogenesis by prolonging ERK activation and increasing p27Kip1. Am J Physiol Cell Physiol 2002; 283: C193-203.
34. Green A. Life and death in the microcirculation: A role for angiotensin II. Microcirc 1998; 5: 101-7.
35. Munzenmaier D, Greene A. Opposing actions of angiotensin II in cultured rat vascular smooth muscle cells. Hypertension 1996; 27: 759-65.
36. Fernandez L, Twickler A, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141-5.
37. Gimbrone M, Cotran R, Leapman S, Folkman J. Tumor growth and neovascularization: An experimental model using the rabbit cornea. J Natl Cancer Inst 1974; 52: 413-27.
38. Le Noble F, schreurs N, van Straaten H, Slaaf D, Smits J, Rogg H, et al. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am J Physiol 1993; 264: R460-R5.
39. 2 receptor mediates inhibiton of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651-7.
40. Tamarat R, Silvestre J, Duriez M, Levy B. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor and inflammation-related pathways. Lab Invest 2002; 82: 747-56.
41. Walsh D, Hu D-E, Wharton J, Catravas J, Blake D, Fan T-P. Sequential development of angiotensin receptors and angiotensin I converting enzyme during angiogenesis in the rat sbucutaneous sponge granuloma. Br J Pharmacol 1997; 120: 1302-11.
42. Chua C, Hamdy R, Chua B. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Act 1998; 1401: 187-94.
43. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-28.
44. Richard D, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: Signals that bridge the gap. Oncogene 2001; 20: 1556-62.
45. Otani A, Takagi H, Oh H, Suzuma K, Matsumura M, Ikeda E, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000; 41: 1192-9.
46. Otani A, Takagi H, Oh H, Koyama S, Honda Y. Angiotensin II induces expression of the Tie2 receptot ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes 2001; 50: 867-75.
47. Rizkalla B, Forbes J, Cooper M, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003; 14: 3061-71.
48. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am J Physiol Heart Circ Physiol 2001; 280: H885-H91.
49. Amaral S, Linderman J, Morse M, Greene A. Angiogenesis induced by electrical stimulation is mediated by angiotensin II and VEGF. Microcirculation 2001; 8: 57-67.
50. Delafontaine P, Lou H. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem 1993; 268: 16866-70.
51. Ververis J, Ku L, Delafontaine P. Regulation of insulin-like growth factor I receptors on vascular smooth muscle cells by growth factors and phorbol esters. Circ Res 1993; 72: 1285-92.
52. Scheidegger K, Du J, Delafontaine P. Distinct and common pathways in the regulation of insulin-like growth factor-1 receptor gene expression by angiotensin II and basic fibroblast growth factor. J Biol Chem 1999; 274: 3522-30.
53. Naftilan A, Pratt R, Dzau V. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1419-24.
54. Peng H, Moffett J, Myers J, Fang X, Stachowiak E, Maher P, et al. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell 2001; 12: 449-62.
55. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, et al. Angiotensin AT1 and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 2001; 88: 22-9.
56. Yamada T, Akishita M, Pollman M, Gibbons G, Dzau V, Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: An in vitro gene transfer study. Life Sci 1998; 63: 289-95.
57. Tea B, Sarkissian S, Touyz R, Hamet P, DeBlois D. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 2000; 35: 1069-73.
58. Nora E, Muzenmaier D, Hansen-Smith F, Lombard J, Greene A. Localization of the ANG II type 2 receptor in the microcirculation of skeletal muscle. Am J Physiol 1998; 275: H1395-403.
59. Ohkubo N, Matsubara H, Nozawa Y, Y M, Murasawa S, Kijima K, et al. Angiotensin type 2 receptors are re-expressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96: 3954-62.
60. Janiak P, Pillon A, Prost J, Vilaine JP. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992; 20: 737-45.
61. Cao Z, Dean R, Wu L, Casley D, Cooper M. Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. Hypertension 1999; 34: 408-14.
62. Takeda H, Katagata Y, Hozumi Y, Kondo S. Effects of angiotensin II receptor signaling during skin wound healing. Am J Pathol 2004; 165: 1653-62.
63. Yamada H, Akishita M, Lto M, Tamura Y, David L, Lehtonen J, et al. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999; 33: 1414-9.
64. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke prone hypertensive rats. Hypertension 1997; 29: 478-82.
65. Colman R, Jameson B, Lin Y, Johnson D, Mousa S. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 2000; 95: 543-50.
66. Gun Y, Wang S, Colman R. Kininostatin an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 1427-33.
67. 9-bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats. Br J Pharmacol 1993; 109: 14-7.
68. Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis M, et al. Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 2001; 103: 125-32.
69. Colman R, Pixley R, Sainz I, Song J, Isordia-Salas I, Muhamed S, et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003; 1: 164-70.
70. Song J, Sainz I, Cosenza S, Isordia-Salas I, Bior A, Bradford H, et al. Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood 2004; 104: 2065-72.
71. Piendi J, Snyman C, Naidoo S, Sawant S, Mahabeer R, Bhoola K. Expression of tissue kallikrein and kinin receptors in angiogenic microvascular endothelial cells. Biol Chem 2000; 381: 1103-15.
72. Morbidelli L, Parenti A, Giovanelli L, Granger H, Ledda F, Ziche M. B1 receptor involvement in the effect of bradykinin on venular EC proliferation and potentiation of FGF-2 effects. Br J Pharmacol 1998; 124: 1288-92.
73. Silvestre J, Bergaya, S, Tamarat R, Duriez M, Boulanger C, Levy B. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001; 89: 678-83.
74. Erman A, Winkler J, Chem-Gal B, Rabinov M, Zelykovski A, Tadjer S, et al. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. J Hypertens 1991; 9: 1057-62.
75. Piepho R. Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharin 2000; 57: 53-7.
76. Molteni A, Ward W, Ts'ao, C, Taylor J, Small WJ, Brizio-Molteni L, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Current Pharm Design 2003; 9: 751-61.
77. Molteni A, Ward W, Ts'ao C, Solliday N. Monocrotaline induced pulmonary vascular damage in rats: Amelioration by CL 242817, a new angiotensin converting enzyme inhibitor. Proc Soc Exp Biol Med 1986; 182: 483-93.
78. Molteni A, Ward W, Ts'ao C, Solliday N. Monocrotaline-induced cardiopulmonary injury in rats: Modification by thiol and nonthiol ACE inhibitors. Clin Exp Hypertens A 1987; 9: 381-5.
79. Ward W, Molteni A, Ts'ao C. Radiation-induced endothelial dysfunction and fibrosis in rat lung: Modification by the angiotensin converting enzyme inhibitor CL 242817. Radiat Res 1989; 117: 342-50.
80. Molteni A, Ward W, Ts'ao C, Solliday N. Monocrotaline-induced cardiopulmonary injury in rats: Modification by the nonthiol ACE inhibitors CGS 13945 and CGS 16617. Arch Int Pharmacodyn Ther 1988; 291: 21-40.
81. Molteni A, Ward W, Ts'ao, C, Solliday N, Dunne M. Prevention of monocrotaline-induced pulmonary fibrosis in the rat by administration of captopril and penicillamine. Proc Soc Exp Biol Med 1985; 180: 112-20.
82. Ward W, Molteni A, Ts'ao C, Solliday N. Functional responses of the pulmonary endothelium to thoracic irradiation in rats: Differential modification by D-penicillamine. Int J Radiat Oncol Biol Phys 1987; 12: 1505-13.
83. O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses MWS, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
84. Gately S, Twardowdki P, Stack M, Cundiff D, Grella D, Castellino F, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94: 10868-72.
85. De Groot-Besseling R, Ruers T, van Kraats A, Poelen G, Rutter D, De Waal R, et al. Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 2004; 112: 329-34.
86. Merchan J, Chan B, Kale S, Schnipper L, Sukhatme V. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003; 95: 388-99.
87. Volpert O, Ward W, Lingen M, Chesler L, Solt D, Johnson M, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-9.
88. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81: 761-6.
89. Hii S-I, Nicol D, Gotley D, Thompson L, Green M, Jonsson J. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880-3.
90. Ward W, Molteni A, Ts'ao C, Hinz J. The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990; 63: 349-54.
91. Vogt B, Frey F. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997; 349: 1148.
92. Ishihara, K, Hayash, Yamashina S, Majima M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol 2001; 87: 318-26.
93. Qiu J, Factor S, Chang T, Knighton D, Nadel H, Levenson S. Wound healing: Captopril, an angiogenesis inhibitor, and Staphylococcus aureus peptidoglycan. J Surg Res. 2000; 92: 177-85.
94. Tadesse M, Yan Y, Yossuck P, Higgins R. Captopril improves retinal neovascularization via endothelin-1. Invest Ophthalmol Vis Sci 2001; 42: 1867-72.
95. Kalkman E, van Haren P, Saxena, P, Schoemaker R. Early captopril prevents myocardial infarction-induced hypertrophy but not angiogenesis. Eur J Pharmacol 1999; 369: 339-48.
96. Gavin T, Spector D, Wagner H, Breen E, Wagner P. Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise. J Appl Physiol 2000; 88: 1690-7.
97. Hausman G, Richardson R. Adipose tissue angiogenesis. J Anim Sci 2004; 82: 925-34.
98. Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: Involvement in adipose differentiation. Diabetes 2001; 50: 2080-6.
99. Galt S, Lindemann S, Allen L, Medd D, Falk J, McIntyre T, et al. Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 2002; 90: 1093-9.
100. Kang Q, Cao Y, Zolkiewska A. Metalloprotease-disintegrin ADAM 12 binds to the SH3 domain of Src and activates Src tyrosine kinase in C2C12 cells. Biochem J 2000; 352: 883-92.
101. Kohlstedt K, Brandes R, Muller-Esterl W, Busse R, Fleming I. Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 2004; 94: 60-7.
102. Emanueli C, Salis M, Stacca T, Pinna A. Gaspa L, Spano A, et al. Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats. Am J Hypertens 2002; 15: 410-5.
103. Fernandez L, Caride V, Twickler J, Galardy R. Renin-angiotensin and development of collateral circulation after renal ischemia. Am J Physiol 1982; 243: H869-75.
104. Clozel J, Kuhn H, Hefti F. Effects of cilazapril on the cerebral circulation in spontaneously hypertensive rats. Hypertension 1989; 14: 645-51.
105. Clozel J, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989; 7: 267-75.
106. Olivetti G, Cigola E, Lagrasta C, Ricci R, Quaini F, Monopoli A, et al. Spirapnil prevents left ventricular hypertrophy, decreases myocardial damage and promotes angiogenesis in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1993; 21: 362-70.
107. Cameron N, Cotter M, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-8.
108. Li D-Y, Zhao K, Zhou J-F, Chen P, Li W. Changes of expression of VEGF, bFGF, and angiogenesis, and effect of benazepril, bFGF, on angiogenesis in acute myocardial infarction model of the rabbits. Biomed Environ Sci 2004; 17: 442-51.
109. Silvestre J, Kamsu-Kom N, Clergue M, Duriez M, Levy B. Very-low dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther 2002; 303: 1038-43.
110. Rakugi H, Jacob H, Krieger J, Ingelfinger J, Pratt R. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 1993; 87: 283-90.
111. Fabre J-E, Rivard A, Magner MM, Isner J. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation 1999; 99: 3043-9.
112. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, et al. Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension 1992; 20: 478-82.
113. Hayashi I, Amano H, Yoshida S, Kamata K, Kamata M, Inukai M, et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 2002; 82: 871-80.
114. Ebrahimian T, Tamarat R, Clergue M, Duriez M, Levy B, Silvestre J. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 2005; 25: 65-70.
115. Emanueli C, Salis M, Stacca T, Pintus G, Kirchmair R, Isner J, et al. Targeting Kinin B1 receptor for therapeutic neovascularization. Circulation 2002; 105: 360-6.
116. Sangree S, Brovkovych V, Minshall R, Skidgel R. Regulation of cardiovascular signaling by kinins and products of similar converting enzyme systems. Kininase I-type carboxypeptidases enhance nitric oxide production in endothelial cells by generating bradykinin B1 receptor agonists. Am J Physiol Heart Circ Physiol 2003; 284: H1959-68.
117. Marin-Castano M, Schanstra J, Neau E, Praddaude F, Pecher C, Ader et al. Induction of functional bradykinin B1-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 2002; 105: 627-32.
118. Kang D, Ryberg K, Morgelin M, Leeb-Lundberg L. Spontaneous formation of a proteolytic B1 and B2 bradykinin receptor complex with enhanced signaling capacity. J Biol Chem 2004; 279: 22102-7.
119. Tamarat R, Silvestre J, Kubis N, Benessiano J, Duriez M, DeGasparo M, et al. Endothelial nitric oxide synthase lies downstream from angiotensin II-induced angiogenesis in ischemic hindlimb. Hypertension 2002; 39: 830-5.
120. Silvestre J, Tamarat R, Senbonmatsu T, Icchiki T, Ebrahimian T, Iglarz M, et al. Antiangiogenic effect of angiotensin II type 2 receptors in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2002; 90: 1072-9.
121. Murohara T, Takayuki A, Silver M, C Masuda H, Kalka C, Kearney M, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567-78.
122. Maxfield E, Cameron N, Cotter M, Dines K. Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function. Diabetologia 1993; 36: 1230-7.
123. Forder J, Munzenmaier D, Greene A. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am J Physiol Heart Circ Physiol 2005; 288: H1989-96.
124. Ito T, Yamakawa H, Bregonzio C, Terron J, Falcon-Neri A, Saavedra M. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002; 33: 2297-303.
125. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pre-treatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21: 2175-82.
126. Fernandez L, Spencer D, Kaczmar M. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986; 17: 82-5.
127. Fernandez L, Caride V, Stromberg C, Naveri L, Wicke J. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994; 24: 937-40.
128. Kaliszewski C, Fernandez L, Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbel: Role of endogenous angiotensin II. J Cereb Blood Flow Metab 1988; 8: 149-54.
129. Murata M, Nakagawa M, Takahashi S. Expression and localization of angiotensin II type 1 receptor mRNA in rat ocular tissues. Ophthalmologica 1997; 211: 384-6.
130. Ramirez M, Davidson E, Luttenauer L, Elena P, Cumin F, Mathis G, et al. The renin-angiotensin system in the rabbit eye. J Ocul Pharmacol Ther 1996; 12: 299-312.
131. Wheeler-Schilling T, Kohler K, Sautter M, Guenther E. Angiotensin II receptor subtype gene expression and cellular localization in the retina and non-neuronal ocular tissues of the rat. Eur J Neurosci 1999; 11: 3387-94.
132. Danser A, Derkx F, Admiraal P, Deinum J, Dejong P, Schalekamp M. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18.
133. Moravski C, Kelly D, Cooper M, Gilbert R, Bertram J, Shahinfar S, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000; 36: 1099-104.
134. Sarlos S, Rizkalla B, Moravski C, Cao Z, Cooper M, Wilkinson-Berka J. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 2003; 163: 879-87.
135. Lonchampt M, Pennel L, Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: A role for angiotensin II. Invest Ophthalmol Vis Sci 2001; 42: 429-32.
136. Nakamura H, Inoue T, Arakawa N, Shimizu Y, Yoshigae Y, Fujimori I, et al. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. Eur J Pharmacol 2005; 512: 239-46.
137. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2005; 46: 1078-84.
138. Higgins R, Yan Y, Geng Y, Sharma J, Barr S. Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr Eye Res 2003; 27: 123-9.
139. Gerber H, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bc1-2 and Al in vascular endothelial cells. J Biol Chem 1998; 273: 13313-6.
140. Danser A, Van den Dorpel M, Deinum J, Derkx F, Franken A, Peperkamp E, et al. Renin, prorenin, and immunreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metabol 1989; 68: 160-7.
141. Zhang X, Lassila M, Cooper M, Cao Z. Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004; 43: 276-81.
142. Moravski C, Skinner S, Stubbs A, Sarlos S, Kelly D, Cooper M, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes. Am J Pathol 2003; 162: 151-60.
143. Gilbert R, Kelly D, Cox A, Wilkinson-Berka J, Rumble J, Osicka T, et al. Angiotensin converting enzyme inhibition reduced retinal overexpression of vascular endothelial growth factor and hyper-permeability in experimental diabetes. Diabetologia 2000; 43: 1360-7.
144. Dosso A, Rungger-Brandle E, Leuenberger P. Ultrastructural alterations in capillaries of the diabetic hypertensive rat retina: Protective effects of ACE inhibition. Diabetologia 2004; 47: 1196-201.
145. Chaturvedi N, Sjolie A-K, Stephenson J, Abrahamian H, Keipes, MCastellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.
146. Group UPDS. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br J Med 2005; 317: 713-20.
147. Ronquist G, Rodriguez L, Ruigomez A, Johansson S, Wallander M-A, Frithz G, et al. Association between captopril, other anti-hypertensive drugs and risk of prostate cancer. The Prostate 2004; 58:50-6.
148. Lever A, Hole D, Gillis C, IR M, McInnes G, MacKinnon P, et al. Do inhibitors of angiotensin-1 -converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
149. Pahor M, Guralnik J, Salive M, Corti M-c, Carbonin P, Havlik R. Do calcium channel blockers increase the risk of cancer? Am J Hyperten 1996; 9: 695-9.
150. Jick H, Jick S, Derby L, Vasilakis C, Myers M, Meier C. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
151. Friis S, Sorensen H, Mellemkjaer L, McLaughlin J, WJ, Olsen J. Angiotensin-converting enzyme inhibitors and the risk of cancer. Cancer 2001; 92: 2462-70.
152. Meier C, Derby L, Jick S, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-53.
153. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez L. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004; 13: 581-5.
154. Li C, Malone K, Weiss N, Boudreau D, Cushing-Haugen K, Daling J. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003; 98: 1504-13.
155. Fitzpatrick A, Daling J, Furberg C, Kronmal R, Weissfeld J. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80: 1438-47.
156. Perron L, Bairati I, Harel F, Meyer F. Antihypertenisve drug use and the risk of prostate cancer. Cancer Causes Control 2004; 15: 535-41.
157. Stahl M, Bulpitt C, Palmer A, Beevers D, Coles E, Webster J. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: A report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hyperten 2000; 14: 299-304.
158. Rosenberg L, Rao S, Palmer J, Strom B, Stolley P, Zauber A, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279: 1000-4.
159. Lindholm L, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in old patients with hypertension 2: A 5-year prospective, randomised, controlled trial. Lancet 2001; 358: 539-44.
160. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1992;327:685-91.
161. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
162. Grossman E, Messerli F, Goldbourt U. Antihypertensive theraphy and the risk of malignancies. Eur Heart J 2001; 22: 1343-52.
163. Koh W-P, Yuan J-M, Sun C-L, van den Berg D, Seow A, Lee H-P, et al. Angiotensin 1-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003; 63: 573-8.
164. Haiman C, Henderson S, Bretsky P, Kolonel L, Henderson B. Genetic variation in angiotensin 1-converting enzyme (ACE) and breast cancer risk: The multiethnic cohort. Cancer Res 2003; 63: 6984-7.
165. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, et al. The angiotensin I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073-8.
166. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002; 20: 1227-31.
167. Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, et al. Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep 2005; 13: 491-5.
168. Heffelfinger S, Yassin R, Miller M, Lower E. Vascularity of proliferative breast disease and carcinoma in situ correlates with histologic features. Clinical Cancer Res 1996; 2: 1873-8.
169. Heffelfinger S, Yan M, Gear R, Schneider J, LaDow K, Warshawsky D. Inhibition of VEGFR2 Prevents DMBA-Induced Mammary Tumor Formation. Lab Invest 2004; 84: 989-98.
170. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22-30.
171. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, et al. Effects of the angiotensin-1 converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 2004; 130: 567-73.
172. Molteni A, Lally J, Small W, Dobbs L, Veno P. Delayed growth of the MA-16 mammary carcinoma in mice treated with the angiotensin converting enzyme inhibitor captopril. FASEB J 1998; A-97.
173. Hori K, Saito S, Takahashi H, Sato H, Maeda H, Sato Y. Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res 2000; 91: 261-9.
174. Jiang H, Li Z, Xu G, Tu Z, Gong Y. Angiotensin II type 1 receptor mRNA and its protein expression in human pancreatic cancer cell lines. Chin J Dig Dis 2004; 5: 68-71.
175. Brechler V, Jones P, Levens N, de Gasparo M, Bottari S. Agonistic and antagonistic properties of angiotensin analogs at the AT2 receptor in PC12W cells. Regul Pept 1993; 44: 207-13.
176. Muscella A, Greco S, Elia M, Storelli C, Marsigliante S. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 2002; 173: 315-23.
177. Rivera E, Arrieta O, Guevara P, Duarte-Rojo a, Sotelo J. AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br J Cancer 2001; 85: 1396-9.
178. Kucerova D, Zelezna B, Sloncaova E, Sovova V. Angiotensin II receptors on colorectoal carcinoma cells. Internatl J Molec Med 1998; 2: 593-5.
179. Tahmasebi M, Puddefoot J, Inwang E, Goode A, Carpenter R, Vinson G. Transcription of the prorenin gene in normal and diseased breast. Eur J Cancer 1998; 34: 1777-82.
180. De Paepe B, Verstraeten V, De Potter C, Vakaet L, Bullock G. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001; 116: 247-54.
181. De Paepe B, Verstraeten V, De Potter C, Bullock G. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS, and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002; 117: 13-9.
182. Inwang E, Puddefoot J, Brown C, Goode A, Marsigliante S, Ho M, et al. Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 1997; 75: 1279-83.
183. Walther T, Menrad A, Orzechowski H, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003; 17: 2061-7.
184. Guerra F, Ciuffo G, Elizalde P, Charreau E, Saavedra J. Enhanced expression of angiotensin II receptor subtypes and angiotensin converting enzyme in medroxyprogesterone-induced mouse mammary adenocarcinomas. Biochem Biophys Res Commun 1993; 193: 93-9.
185. Small WJ, Molteni A, Kim Y, Taylor J, Chen Z, Ward W. Captopril modulates hormone receptor concentrations and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast cancer Res Treat 1997; 44: 217-24.
186. Small WJ, Molteni A, Kim Y, Taylor J, Ts'ao C, Ward W. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res Treat 1999; 55: 223-9.
187. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001; 158: 1633-7.
188. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001; 495: 197-200.
189. Reddy M, Baskaran K, Molteni A. Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995; 210: 221-6.
190. Miyajima A, Kosaka, T, Asano T, Asano, T, Seta K, Kawai T, et al. Angtiotensin II type 1 antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176-9.
191. Goldfarb D, Diz D, Tubbs R, Ferrario C, Novick A. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J Urol 1994; 151: 208-13.
192. Ariza A, Fernandez L, Inagami T, Kim J, Manuelidis E. Renin in glioblastoma multiforme and its role in neovascularization. Am J Clin Pathol 1988; 90: 437-41.
193. Fogarty D, Sanchez-Gomez M, Matute C. Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 2002; 39: 304-13.
194. Maggi M, Finetti G, Cioni A, Mancina R, Baldi E, Serio M, et al. Identification and characterization of functional angiotensin II receptors in human neuroblastoma cells. Regul Pept 1995; 56: 175-84.
195. Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I, et al. Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Internatl J Oncol 2003; 23: 593-8.
196. Shibata K, Kikkawa F, Mizokami Y, Kajiyama H, Ino K, Nomura S, et al. Possible involvement of adipocyte-derived leucine aminopeptidase via angiotensin II in endometrial carcinoma. Tumor Biol 2005; 26: 9-16.
197. Egami K, Murohara T, Shimada T, Sasaki K-I, Shintani S. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67-75.
198. Fujita M, Hyashi I, Yamashina S, Fukamizu A, Itoman M, Majima M. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 271-9.
199. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2: 1139-47.
200. Takagi T, Nakano Y, Takekoshi s, Inagami T, Tamura M. Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2002; 23: 1235-41.
201. Bunn PJ, Chan D, Dienhart D, Tolley R, Tagawa, M, Jewett P. Neuropeptide signal transduction in lung cancer: Clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res 1992; 52: 24-31.
202. Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K. Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer 2002; 98: 29-35.
203. Barki-Harrington L, Bookout A, Want G, Lamb M, Leeb-Lundberg L. Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells. Biochem J 2003; 371: 581-7.
204. Drube S, Liebmann C. In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist. Br J Pharmacol 2000; 131: 1553-60.
205. Greco S, Muscella A, Elia M, Romano S, Storelli C, Marsigliante S. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. J Cell Physiol 2004; 201: 84-96.
206. Taub J, Guo R, Leeb-Lundberg L, Madden J, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003; 63: 2037-41.
207. Clements J, Mukhtar A. Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. Immunopharmacology 1997; 36: 217-20.
208. Ikeda Y, Hayashi I, Kamoshita E, Yamazaki A, Endo H, Ishihara K, et al. Host stromal bradykinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004; 64: 5178-85.
209. Ishihara, K, Kamata M, Hayashi I, Yamashina S, Majima M. Roles of bradykinin in vascular permeability and angiogenesis in solid tumor. Int Immunopharmacol 2002; 2: 499-509.
210. Phagoo S, Poole S, Leeb-Lundberg L. Autoregulation of bradykinin receptors: Agonists in the presence of interleukin-1β shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. Mol Pharmacol 1999; 56: 325-33.
211. Leeb-Lundberg L, Kang D, Lamb M, Fathy D. The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. J Biol Chem 2001; 276: 8785-92.
212. Stewart J, Chan D, Simkevicience V, Bunn PJ, Helfrich B, York E, et al. Bradykinin antagonists as new drugs for prostate cancer. Internatl Immunopharmacol 2002; 2: 1781-6.
213. Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci USA 2002; 99: 4608-13.
214. Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr Pharm Des 2006; 12(21): 2599-607.
215. Lazarovici P, Marcinkiewicz C, Lelkes PI. Cross talk between the cardiovascular and nervous systems: Neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 2006; 12(21): 2609-22.
216. Su JB. Kinins and cardiovascular diseases. Curr Pharm Des 2006; 12(26): 3423-35.